Montag A & Associates Inc. Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Montag A & Associates Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 82.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139 shares of the biopharmaceutical company's stock after selling 644 shares during the quarter. Montag A & Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $99,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of REGN. Mizuho Securities USA LLC raised its holdings in shares of Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock worth $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock worth $10,082,000 after purchasing an additional 3,231 shares during the period. Golden State Equity Partners raised its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 1,272 shares during the period. Finally, ABC Arbitrage SA bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,510,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $4.31 during trading on Friday, hitting $700.33. The company's stock had a trading volume of 727,332 shares, compared to its average volume of 923,518. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The firm has a market cap of $76.56 billion, a PE ratio of 18.29, a P/E/G ratio of 2.30 and a beta of 0.08. The business's 50 day simple moving average is $699.40 and its 200-day simple moving average is $883.75.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm earned $11.86 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.